Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in North Carolina: - Cone Health Cancer Center at Asheboro — Asheboro, North Carolina
- Cone Health MedCenter Asheboro — Asheboro, North Carolina
- AdventHealth Infusion Center Asheville — Asheville, North Carolina
- Cone Health Cancer Center at Alamance Regional — Burlington, North Carolina
- UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
Phase 3 Recruiting Academic/Other
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…
Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in North Carolina: - Atrium Health Stanly/LCI-Albemarle — Albemarle, North Carolina
- Mission Hospital — Asheville, North Carolina
- Hope Women's Cancer Centers-Asheville — Asheville, North Carolina
- Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
- Novant Health Presbyterian Medical Center — Charlotte, North Carolina
Phase 3 Recruiting Academic/Other
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in North Carolina: - Duke Cancer Center Cary — Cary, North Carolina
- UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
- Novant Health Presbyterian Medical Center — Charlotte, North Carolina
- Novant Health Colon and Rectal Clinic — Clemmons, North Carolina
- Southeastern Medical Oncology Center-Clinton — Clinton, North Carolina
Phase 3 Recruiting Industry
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…
Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in North Carolina: - Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
- Novant Health Cancer Institute - Elizabeth (Breast) — Charlotte, North Carolina
- Duke Cancer Institute — Durham, North Carolina
- Cone Health Medical Group (Moses Cone Health System) — Greensboro, North Carolina
- East Carolina University Health Medical Center — Greenville, North Carolina
Phase 3 Recruiting Industry
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early b…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06492616
Sites in North Carolina: - Duke Cancer Institute — Durham, North Carolina
- Cape Fear Valley Medical Center — Fayetteville, North Carolina
- Cone Health Cancer Center at Wesley Long — Greensboro, North Carolina
Phase 3 Recruiting Industry
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBC…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05827081
Sites in North Carolina: - Duke Cancer Network — Durham, North Carolina
- Cone Health Cancer Center — Greensboro, North Carolina
Phase 3 Recruiting Industry
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribo…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06065748
Sites in North Carolina: - Duke Women Cancer Care — Raleigh, North Carolina
Phase 3 Recruiting Industry
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in North Carolina: - Duke Cancer Institute — Durham, North Carolina
Phase 3 Recruiting Industry
The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metasta…
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06435429
Sites in North Carolina: - Messino Cancer Center — Asheville, North Carolina
- Duke Cancer Institute — Durham, North Carolina
- UNC Central Investigational Drug Services — Morrisville, North Carolina
Phase 3 Recruiting Industry
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who ha…
Sponsor: LeonaBio
NCT ID: NCT05696626
Sites in North Carolina: - Duke University Medical Center — Durham, North Carolina
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in North Carolina: - Cone Health MedCenter Asheboro — Asheboro, North Carolina
- Cone Health Cancer Center at Alamance Regional — Burlington, North Carolina
- Southeastern Medical Oncology Center-Clinton — Clinton, North Carolina
- Duke University Medical Center — Durham, North Carolina
- Southeastern Medical Oncology Center-Goldsboro — Goldsboro, North Carolina
Phase 2 Recruiting Industry
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in North Carolina: - UNC Hospitals, University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in North Carolina: - Regional Medical Oncology Center — Wilson, North Carolina
Phase 2 Recruiting Industry
The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT07102381
Sites in North Carolina: - Levine Cancer — Charlotte, North Carolina
Phase 1, Phase 2 Recruiting Industry
This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages. During Stage 1, seven …
Sponsor: Hoffmann-La Roche
NCT ID: NCT03424005
Sites in North Carolina: - Duke Cancer Institute — Durham, North Carolina
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination…
Sponsor: ORIC Pharmaceuticals
NCT ID: NCT05315700
Sites in North Carolina: - Duke Cancer Institute — Durham, North Carolina
Phase 1, Phase 2 Recruiting Industry
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatmen…
Sponsor: Hoffmann-La Roche
NCT ID: NCT04802759
Sites in North Carolina: - Levine Cancer Institute — Charlotte, North Carolina
Phase 2 Recruiting Academic/Other
This is a randomized Phase II study of standard of care (SOC) chemotherapy monotherapy vs. SOC chemotherapy combined with tocilizumab in in Black and non-Black patients with metastatic triple negative or ER low breast cancer.
Sponsor: Kathy Miller
NCT ID: NCT05846789
Sites in North Carolina: - Duke University — Durham, North Carolina
Phase 1, Phase 2 Recruiting Industry
This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors. This is an open-label study which means that participants and study staff will…
Sponsor: Arvinas Inc.
NCT ID: NCT07749586
Sites in North Carolina: - Clinical Trial Site — Huntersville, North Carolina
Phase 2 Recruiting Academic/Other
The purpose of this study is to test the safety and effectiveness of the study drug datopotamab deruxtecan in participants with metastatic breast cancer that has spread to the brain. The name of the study drug used in this research study i…
Sponsor: Nancy Lin, MD
NCT ID: NCT06176261
Sites in North Carolina: - Duke University Medical Center — Durham, North Carolina
Phase 2 Recruiting Academic/Other
This is a 4-arm, single-center study involving 40 participants. Ten healthy volunteers will be enrolled for system imaging optimization, and thirty (30) patients with previously identified lesions in the breast, liver, or kidney-based on p…
Sponsor: UNC Lineberger Comprehensive Cancer Center
NCT ID: NCT07225114
Sites in North Carolina: - The University of North Carolina — Chapel Hill, North Carolina
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this study is to evaluate the intracranial response rate of a combination of asciminib/trastuzumab for the treatment of patients with metastatic HER2+ breast cancer with brain metastases.
Sponsor: Duke University
NCT ID: NCT07136428
Sites in North Carolina: - Duke University — Durham, North Carolina
Phase 1 Recruiting Industry
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in North Carolina: - Duke Cancer Institute — Durham, North Carolina
Phase 1 Recruiting Industry
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumo…
Sponsor: Exelixis
NCT ID: NCT06545331
Sites in North Carolina: - Carolina BioOncology Institute — Huntersville, North Carolina
Phase 1 Recruiting Industry
This is a Phase 1b open-label, 2-part study in 3 treatment groups. The 3 treatment groups are as follows: Treatment Group 1: Palazestrant (OP-1250) in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation). Treatment …
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT05508906
Sites in North Carolina: - Atrium Health Levine Cancer Institute — Charlotte, North Carolina